All News
TNF Inhibitor Induced Psoriasis
Tumor necrosis factor-α inhibitors (TNFi) rarely have been reported to induce new-onset psoriasis.
Read ArticleMortality in Gout Increased
Two current articles in the Journal of Rheumatology address issues surrounding mortality risk among those with new and established gout.
Read ArticleICER Report Claims RA Drugs are Not Cost Effective
On Friday March 24, the nonprofit Institute for Clinical and Economic Review (ICER) presented its report on the cost and value of targeted immune modulators (TIMs) for rheumatoid arthritis (RA) in a meeting in Boston that included clinical experts, manufacturers, payers, and patients.
Read ArticleBiologics Do Not Increase Melanoma Risk
Rheumatoid arthritis (RA) patients have a higher risk of certain cancers (e.g., skin, lung, lymphoma). At issue is whether the newer agents modify this risk appreciably.
Read ArticleSteroids, DMARDs and Biologics have Same Low Risk of Infection During Pregnancy
Low rates of serious infections were observed in pregnant women receiving immunosuppressive therapies. Higher rates may be seen with steroid use in pregnancy and SIE trend towards lowest with DMARD or TNFi use.
Read ArticleLyrica Fails in Sciatica Pain
Lyrica (pregabalin) was first approved in 2004 and since has been studied and approved for use in neuropathic pain (associated with diabetic neuropathy), postherpetic neuralgia, partial onset seizures, fibromyalgia and neuropathic pain with spinal cord injury.
Read ArticleThe RheumNow Week in Review – 24 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com.
Read ArticleNEJM Reviews Psoriatic Arthritis
A comprehensive review of psoriatic arthritis (PsA) was published this week in the NEJM, authored by leaders in the field, Drs. Ritchlin, Colbert and Gladman.
High points from their review inlcuded:
Read ArticleSjogren's Syndrome Foundation's 2017 Sjogren's Treatment Guidelines
Dr. Steven Carsons and an expert committee of the Sjogren's Syndrome Foundation have published a clinical practice guidelines (CPGs) and recommendations for the managment of Sjögren's syndrome.
Read ArticleLimited Benefits with Intra-Discal Steroid Injections for Back Pain
A a randomized trial published in Annals of Internal Medicine shows that intradiscal glucocorticoid injection has limited (1 month) efficacy in treating low back pain (LBP) associated with active discopathy, yet decreased over time.
Read ArticleCause of Death in Ankylosing Spondylitis
A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology.
They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009).
Read ArticleCheckpoint Inhibitors Causing Rheumatic Disease
Calabrese and Velcheti have reviewed the current understanding that underlies a new drug-induced rheumatic disease - checkpoint inhibitor arthritis and autoimmune disease.
Read ArticleACR Says the New AHCA is Insufficient for Arthritis Patients
Dr. Sharad Lakhanpal, MBBS, MD, President of the American College of Rheumatology (ACR) has issued a press release condeming the insufficiencies of the newly proposed American Health Care Act (AHCA).
Read ArticleThe RheumNow Week in Review – 17 March 2017
Dr. Jack Cush reviews highlights in the news from the past week at RheumNow.com. News on hepatitis C in RA and risk of hepatotoxicity; TNF inhibitor persistence in PsA; unnecessary injections in pre-operative OA knee patients; and a delay in the FDA decision on abaloparatide.
Read ArticleFDA Invites Open Commentary on Biosimilar Interchangeability
In January 2017, the Food and Drug Administration (FDA) released its draft guidance on the issue of interchangeability between biosimilars and originator biologic drugs. The window for your input will close on May 18, 2017. RheumNow encourages you to participate in this exercise and express your opinion.
Read ArticleThe UnderManagement of Gout
Most physicians believe they understand and can manage gout. Yet, the number of gout patients has risen at an alarming rate and the introduction of 4 new drugs has done little to close the education gap and improve the care and outcomes of gout patients. Misuse, misunderstandings and missed opportunities abound in the wide world of gout.
Read ArticleEULAR Treat-to-Target Guidelines for Gout
Treat-to-target (T2T) works when they are pragmatic and conform well to daily practice.
Gout is an ideal therapeutic area where T2T could be and should be applied.
Read ArticleThe RheumNow Week in Review – 10 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com. Sign up at RheumNow.com to received daily or weekly news, blogs and tweets on all things rheumatology
Read ArticleEuropean Biologic Manufacturers Issue Warnings About Biosimilar Switching
Reuters has reported that European drugmakers have taken the tact of warning EU physician contemplating the switch from existing (originator) biologic therapy to newer, cut-rate biosimilar. Biosimilar use is widespread outside the USA.
Read Article